“在2024年欧洲肿瘤医学学会(ESMO)年会上公布的Cohort-G队列研究数据，为三联疗法的临床获益提供了令人信服的证据。无进展生存期和客观缓解率显着提高，这在CLDN18.2表达水平高╱中且PD-L1表达水平低的患者群体中尤其突出，这充分展示了该治疗方案的潜力，”北京大学肿瘤医院消化肿瘤内科及I期临床试验病区主任，以及本次研究的主要研究者沈琳教授表示，“我们对这种疗法可能为患者带来的积极影响感到高兴。” On September 19, Glanoia announced the updated research data of the G-line queue for the first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma (TranStar102) using Osemitamab (TST001) in combination with Nivolumab and CAPOX. Since the data from this queue was announced at the ASCO 2024 conference, it has consistently shown encouraging efficacy.
The study results showed that in patients with known levels of CLDN18.2 and PD-L1 expression, the median progression-free survival (mPFS) for patients with high/medium expression of CLDN18.2 was 14.2 months, and the confirmed objective response rate was 68%. Most of these patients had PD-L1 CPS <5.
"The updated data from the Cohort-G trial demonstrates the encouraging efficacy of Osemitamab (TST001) in combination with Nivolumab and CAPOX as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma. Compared to patients who do not express CLDN18.2, the confirmed objective response rate and median progression-free survival in patients with high/medium expression of CLDN18.2 and known PD-L1 expression levels confirm the synergistic effect between Osemitamab (TST001) and checkpoint inhibitors. This highlights the potential of the triple therapy and the possibility of benefiting patients with low PD-L1 expression," said Dr. Caroline Germa, Global Head of Drug Development and Chief Medical Officer of the company. "These clinical results underscore the potential of Osemitamab (TST001) in improving the prognosis of patients with advanced gastric or gastroesophageal junction adenocarcinoma."
"The Cohort-G queue research data presented at the 2024 European Society for Medical Oncology (ESMO) Congress provides compelling evidence for the clinical benefits of triple therapy. There is a significant improvement in progression-free survival and objective response rate, particularly in the patient population with high/medium CLDN18.2 expression and low PD-L1 expression levels. This fully demonstrates the potential of this treatment regimen," said Prof. Lin Shen, Director of the Department of Gastrointestinal Oncology and Phase I Clinical Trial Unit at Peking University Cancer Hospital, and the lead investigator of this study. "We are pleased with the positive impact this therapy may bring to patients."
